Tarsus Pharmaceuticals (TARS) EBT Margin (2021 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly EBT Margin of 2.79% for Q1 2026, up 2917.0% year-over-year from 0.09% in Q1 2025, and up 24.95% quarter-over-quarter from 3.72% in Q4 2025.
Powered by 
Analysis
Tarsus Pharmaceuticals (TARS) EBT Margin (2021 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' EBT Margin history runs 6 years deep, the most recent figure standing at 2.79% for Q1 2026.
- In Q1 2026, EBT Margin rose 2917.0% year-over-year to 2.79%; the TTM figure through Mar 2026 stood at 27.39% (up 1664.0% YoY), while the FY2025 annual figure was 14.26%, up 4890.0% from the prior year.
- EBT Margin for Q1 2026 stood at 2.79%, up from 3.72% in the prior quarter.
- The five-year high for EBT Margin was 2.79% in Q1 2026, with the low at 3680.33% in Q1 2022.
- The 5-year median for EBT Margin is 76.64% (2024), against an average of 510.02%.
- Peak annual rise in EBT Margin reached 413830 bps in 2022, while the deepest fall reached 371208 bps in 2022.
- Tarsus Pharmaceuticals' EBT Margin stood at 136.26% in 2022, then plunged by 138 bps to 323.63% in 2023, then surged by 89 bps to 34.76% in 2024, then jumped by 89 bps to 3.72% in 2025, then gained by 25 bps to 2.79% in 2026.
- Business Quant data shows TARS's EBT Margin at 2.79% in Q1 2026, 3.72% in Q4 2025, and 10.69% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Tarsus Pharmaceuticals | 3.96 Bn | 3.51 Bn | 161.80 Mn | -10.56% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.56% |
| Mar 31, 2026 | -2.79% |
| Dec 31, 2025 | -4.11% |
| Sep 30, 2025 | -10.69% |
| Jun 30, 2025 | -19.67% |
| Mar 31, 2025 | -31.96% |
| Dec 31, 2024 | -34.76% |
| Sep 30, 2024 | -48.81% |
| Jun 30, 2024 | -76.64% |
| Mar 31, 2024 | -128.74% |
| Dec 31, 2023 | -324.72% |
| Sep 30, 2023 | -2,081.93% |
| Mar 31, 2023 | -933.72% |
| Dec 31, 2022 | -136.26% |
| Jun 30, 2022 | -35.81% |
| Mar 31, 2022 | -3,680.33% |
| Dec 31, 2021 | -4,271.01% |
| Sep 30, 2021 | -1,265.89% |
| Jun 30, 2021 | 33.11% |
| Mar 31, 2021 | 32.07% |